# Pharmacokinetics of Nilotinib in Subjects With Impaired Hepatic Function and Healthy Subjects With Normal Hepatic Function

> **NCT00418626** · PHASE1 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 27 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Nilotinib

## Key facts

- **NCT ID:** NCT00418626
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-11
- **Primary completion:** 2007-09
- **Final completion:** —
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2012-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00418626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00418626, "Pharmacokinetics of Nilotinib in Subjects With Impaired Hepatic Function and Healthy Subjects With Normal Hepatic Function". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00418626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*